- Home
- LOCL vs APRE Comparison
LOCL vs APRE Comparison
Compare LOCL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCL
- APRE
- Stock Information
- Founded
- LOCL 2021
- APRE 2006
- Country
- LOCL United States
- APRE United States
- Employees
- LOCL N/A
- APRE N/A
- Industry
- LOCL Farming/Seeds/Milling
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOCL Consumer Staples
- APRE Health Care
- Exchange
- LOCL Nasdaq
- APRE Nasdaq
- Market Cap
- LOCL 23.4M
- APRE 20.2M
- IPO Year
- LOCL N/A
- APRE 2019
- Fundamental
- Price
- LOCL $2.40
- APRE $3.35
- Analyst Decision
- LOCL Hold
- APRE Strong Buy
- Analyst Count
- LOCL 1
- APRE 2
- Target Price
- LOCL $1.00
- APRE $15.50
- AVG Volume (30 Days)
- LOCL 5.7K
- APRE 6.4K
- Earning Date
- LOCL 10-28-2024
- APRE 08-12-2024
- Dividend Yield
- LOCL N/A
- APRE N/A
- EPS Growth
- LOCL N/A
- APRE N/A
- EPS
- LOCL N/A
- APRE N/A
- Revenue
- LOCL $31,502,000.00
- APRE $1,275,686.00
- Revenue This Year
- LOCL $94.93
- APRE $96.15
- Revenue Next Year
- LOCL $79.63
- APRE N/A
- P/E Ratio
- LOCL N/A
- APRE N/A
- Revenue Growth
- LOCL 17.53
- APRE 410.91
- 52 Week Low
- LOCL $1.17
- APRE $2.99
- 52 Week High
- LOCL $6.33
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- LOCL 39.21
- APRE 42.35
- Support Level
- LOCL $2.17
- APRE $3.16
- Resistance Level
- LOCL $2.76
- APRE $3.50
- Average True Range (ATR)
- LOCL 0.15
- APRE 0.19
- MACD
- LOCL -0.03
- APRE -0.00
- Stochastic Oscillator
- LOCL 30.26
- APRE 41.38
About LOCL Local Bounti Corporation
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).